J/PR Denver Announces New Travel, Culinary and Lifestyle Account Wins and Office Growth; Elevates Senior Leadership
Denver Office of Global Travel and Hospitality Agency Demonstrates Growth and Expansion
DENVER, May 21, 2025 /PRNewswire/ -- J/PR, a leading global travel and lifestyle agency specializing in public relations, content creation, social media, and brand collaborations, continues to grow and expand in the Denver market with 13 of the agency's clients currently serviced out of Denver and five full time team members.
The growth of the Denver office, located in the vibrant Lower Highlands (LoHi) neighborhood, reflects J/PR's deepening commitment to the thriving Colorado market and its diverse array of travel, hospitality, and lifestyle clients. Since establishing its presence in the market, J/PR has cultivated strong partnerships with some of the region's most esteemed brands. The agency proudly represents a distinguished portfolio of Denver-based clients, including:
Travel: Vail Resorts, Under Canvas, The Clayton Hotel & Members Club, The Ritz-Carlton Denver, The Rally, The ART, a hotel and Great Wolf Lodge Colorado Springs
Culinary: Elway's Downtown, Call Me Pearl, The OG and Milepost Zero
Lifestyle: Fresh Sends and Slumbercloud
To support this growth and further enhance its client service capabilities, J/PR has also announced several key promotions and a recent new hire within its Denver team:
Anna Korte and Audrey Thompson have been promoted to Vice President: In their elevated role, Anna and Audrey continue to provide strategic leadership and drive innovative public relations campaigns for their local, national and global client portfolios. Both Korte and Thompson have been with the agency for nearly 10 years and their deep understanding of the travel and lifestyle sectors has been instrumental in J/PR's success in the Denver market, and beyond.
Betsy Lynch has been promoted to Senior Publicist: Betsy's dedication, strong media relations skills, and keen eye for detail have consistently delivered outstanding results for her clients. This promotion recognizes her growing expertise and contributions to the agency.
Ava Wiesenmeyer has joined J/PR as Publicity Assistant: Ava brings enthusiasm and a strong passion for the industry to the team. She will provide crucial support to senior team members and contribute to the successful execution of client programs.
The expansion of the Denver office underscores J/PR's dedication to fostering strong relationships within the local market and its confidence in the continued growth of the region's travel, hospitality, and lifestyle sectors.
About J/PRJ/PR is a global agency specializing in public relations, social media strategy, photography, content creation, influencer relations, brand strategy, strategic partnerships, and crisis communications, with vast experience in travel, hospitality, destination marketing, lifestyle, real estate, and wellbeing. With offices in New York City, London, Los Angeles, San Diego, San Francisco, Toronto, Denver, Nashville and Arizona, J/PR is renowned for telling the unique and inspiring stories of some of the most coveted brands in the world.
View original content:https://www.prnewswire.com/news-releases/jpr-denver-announces-new-travel-culinary-and-lifestyle-account-wins-and-office-growth-elevates-senior-leadership-302462410.html
SOURCE J Public Relations
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV), developed by Remegen Co., Ltd., and toripalimab (PD-1) combined with CAPOX or trastuzumab as the first-line therapy for HER2-expressing patients with locally advanced or metastatic (la/m) gastric cancer. Comparing to the control group who received standard-of-care therapy, the DV combination therapy demonstrated clinically meaningful efficacy improvement, potentially to benefit patients who are non-responders to traditional targeted therapies. The data presented are from the Phase 2 part of a randomized, multi-cohort, seamlessly connecting Phase 2/3 study, which enrolled systematic chemotherapy-native patients with different HER2 expression levels. As of April 7, 2025, the results showed: Among HER2-overexpressing gastric cancer patients, compared to the PD-1-trastuzumab-CAPOX combination therapy, DV and PD-1 + chemotherapy as well as DV and PD-1 + trastuzumab both demonstrated statistically significant efficacy and favorable safety profiles. Objective response rate (ORR): 66.7% vs 82.4% vs 68.8%; Median progression-free survival (mPFS): NR vs NR vs 14.1 months, with risk of disease progression decreasing by 54%（HR=0.46）and 41% (HR: 0.59); 12-month PFS rate: 66.3%, 67% and 53.6%； Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. In patients with HER2-low-expressing gastric cancer, promising efficacy was observed with DV + PD-1 + CAPOX comparing to PD-1 + CAPOX, with a manageable safety profile. ORR: 72.0% vs 47.8%; mPFS: 9.9 vs 7.2 months, with risk of disease progression decreasing by 31% (HR: 0.69); Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc. Dose optimization conducted in patients with HER2-median/low-expressing gastric cancer. Compared to PD-1 + CAPOX, DV at 2.5 mg/kg or 2.0 mg/kg combined with PD-1 + reduced-dose CAPOX showed significant efficacy, and better safety over the full-dose chemotherapy. ORR: 71.4% vs 66.7% vs 56.3%; 6-month PFS rate: 71.4%，72.7% and 53.3%. Globally, this is the first study to explore the triple combination therapy of "HER2 ADC + PD-1 + targeted medication" as first-line treatment of patients with la/m gastric cancer, pioneering a new mode of synergistic therapy. The multi-cohort design of this study provides precision treatment regimen for gastric cancer patients with different level of HER2 expression. For the HER2-overexpressing gastric cancer patients, DV + PD-1 + trastuzumab has the potential to become the new standard first-line treatment; for the HER2-low-expressing gastric cancer patients, DV + PD-1 + chemotherapy has the potential to fill the treatment gap of these patients. Based on the data obtained from the phase 2 study, the phase 3 clinical study of the triple combination therapy in patients with HER2-median/low-expressing gastric cancer has been initiated in April, 2025, in which 616 participants were planned to be enrolled, to further validate the efficacy of the DV combination therapy. Gastric cancer is the fifth most common malignant tumor in the world, and China accounts for about 42.6% of new cases and 45.0% of deaths worldwide. HER2 is an important target in the treatment of gastric cancer, while the traditional targeted drug trastuzumab is only effective in the population with high expression (IHC 3+ or IHC 2+/FISH+), and can easily become resistant. There is a lack of effective targeted therapy options for patients with low/median HER2 expression (IHC 1+ or IHC 2+/FISH-), and the efficacy of chemotherapy combined with immunotherapy is not satisfactory. As the first domestic HER2-targeted ADC drug in China, DV not only precisely kills tumor cells with HER2 over expression but also attacks adjacent cells with HER2 low expression through the bystander effect. Preclinical studies have also shown that the combination of DV with PD-1 inhibitor and trastuzumab can enhance anti-tumor activity. View original content to download multimedia: SOURCE RemeGen Co., Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors
SAN FRANCISCO and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized by "high potency and low-toxicity" for tumor types such as ovarian cancer and breast cancer, but also validates the advantages of Innovent's ADC technology platform. The results of IBI354 lays the foundation for the subsequent development of Innovent's next-generation of bispecific ADCs and dual-payload ADCs, marking a milestone in Innovent's next-generation "IO+ADC" oncology development strategy. The data presented is from a Phase 1/2 clinical study (NCT05636215) aimed at evaluating the safety, tolerability, and preliminary efficacy of IBI354 in participants with advanced solid tumors. As of March 24, 2025, a total of 368 participants with advanced solid tumors were enrolled and received different doses of IBI354 monotherapy, the median follow-up duration was 11.5 months (range: 0.7-19.6), the median treatment duration was 27.0 weeks (range: 3.1-81.3) and 74 (20.1%) pts were still on treatment. The tumor types including 178 with breast cancer, 92 with ovarian cancer, 38 with colorectal cancer, and 60 with other tumors. IBI354 monotherapy demonstrated excellent safety profile The dosage was escalated to 18mg/kg, with no DLT events observed. The most common treatment-related adverse events (TRAEs) were anemia, nausea, and white blood cell count decreased. The incidence of interstitial lung disease (ILD) was only 1.9%, all were grade 1-2. Overall, 27.4% of patients experienced TRAEs ≥ grade 3, 17.7% experienced TRAEs leading to dose interruption, 2.7% experienced TRAEs leading to dose reduction and 1.6% experienced TRAEs leading to discontinuation, with no TRAEs leading to death. IBI354 monotherapy showed promising efficacy signals in multiple tumor types In HER2-positive breast cancer cohort (n= 88, treated at 6~15mg/kg, the median prior treatment lines was 4), the confirmed objective response rate (ORR) and the disease control rate (DCR) were 59.1% and 90.9%, respectively. In 9 mg/kg Q3W subgroup (n=29), the ORR and the DCR were 72.4% and 89.7%, respectively. The median progression-free survival (PFS) was 14.1 months (95% CI: 8.3-not calculable [NC]) with events of 48.3%. The median overall survival (OS) was immature with events of 3.4%. In ovarian cancer cohort (n=92, treated at 2~12mg/kg, the median prior treatment lines was 3), the cORR was 41.2% and the DCR was 82.0%. In the 12mg/kg Q3W subgroup (n=40), the cORR reached 55.0% and the DCR was 90.0%. In participants with HER2 1+ (n=27), the ORR reached 55.6% and the DCR was 88.9%. As of the data cutoff date, the median follow-up time was 11.9 months, and the median PFS was 7.1 months (95% CI: 5.2−10.8) in 12mg/kg Q3W dose group. The median OS was not mature with events in 14 (34.1%) pts and a 12-month OS rate of 63.9% (95% CI: 45.0−77.8). Professor Qi Zhou, Chief Physician at the Gynecologic Oncology Center of Chongqing University Affiliated Cancer Hospital and the Principal Investigator of the gynecologic oncology cohort study, stated, "The treatment of platinum-resistant recurrent ovarian cancer is difficult and the prognosis is poor, threatening the life and health of women. Extending PFS and OS in platinum-resistant recurrent ovarian cancer patients remains a clinical challenge for gynecological oncologists. ADC drugs provide a new direction for overcoming resistance mechanisms by precisely delivering cytotoxic agents. HER2, as a validated solid tumor target, has made breakthroughs in breast and gastric cancer fields, while the novel ADC drug IBI354 shows broad-spectrum antitumor activity through unique design in HER2 low-expression (IHC 1+) platinum-resistant ovarian cancer. In the Phase 1 study with a dose of 12mg/kg Q3W, IBI354 demonstrated an ORR of 55.0% and DCR of 90.0%, with a median PFS reaching 7.1 months. The safety profile was very good without common severe interstitial lung disease or ocular toxicity seen in other ADCs. These results significantly outperform traditional chemotherapy regimens, suggesting its potential breakthrough efficacy in the platinum-resistant population. The Phase 3 study of IBI354 in platinum-resistant ovarian cancer (HeriCare-Ovarian01) has been initiated, and I am looking forward to the results, as well as the further validation of the long-term benefits for patients receiving IBI354." Doctor Charlotte Rose Lemech from Scientia Clinical Research Ltd, Australia, stated: "Breast cancer is one of the most common malignant tumors among women globally and remains a leading cause of cancer-related deaths. The amplification or overexpression of HER2 (human epidermal growth factor receptor 2) is recognized as a key driver in the development, progression, and metastasis of breast cancer, with approximately 15%-20% of breast cancer patients exhibiting HER2 overexpression. ADCs have become the new standard treatment for later line HER2 positive breast cancer. In this Phase 1 study, IBI354 has demonstrated encouraging efficacy and safety data, achieving high ORR and DCR especially in 9 mg/kg Q3W subgroup. Long term survival was also achieved with the median PFS of 14.1 months. IBI354 also differentiates itself from other HER2 targeted therapies with its safety profile. The incidence of interstitial lung disease was extremely low and most of the hematological toxicity and gastrointestinal adverse events were mild to moderate and can be effectively managed with standard supportive care. This favorable safety profile enhances the clinical application potential of IBI354 and we look forward to IBI354 achieving more breakthroughs in the field of breast cancer treatment." Dr. Hui Zhou, Senior Vice President of Innovent, stated: "With the rapid development of ADC drugs in the field of tumor treatment, Innovent is steadily advancing its strategic layout in the ADC field. At this year's ASCO conference, we update the safety and efficacy data of IBI354 across various advanced solid tumors. These clinical results not only confirm the potential therapeutic value of IBI354 but also demonstrating Innovent's innovative strength and technological advantages in ADC drug development. The phase 3 study of IBI354 in platinum-resistant ovarian cancer has been initiated, and more clinical studies are also planned. We will continue to invest in next-generation ADC molecules, aiming to address unmet clinical needs and bring patients with more effective and safer treatment options." About IBI354 (Anti-HER2 Antibody-Camptothecin Derivative Conjugate) IBI354 is an innovative HER2-targeted antibody–camptocinin derivative conjugate developed by Innovent's proprietary SoloTx ADC platform. With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors. Innovent Biologics is conducting clinical studies to assess the efficacy and safety of IBI354 for multiple advanced solid tumors. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: （1）Innovent does not recommend the use of any unapproved drug (s)/indication (s). （2）Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
43 minutes ago
- Yahoo
VINEXPO ASIA 2025 OFFERS CLARITY FOR ASEAN TRADE IN SHIFTING LANDSCAPE
SINGAPORE, June 3, 2025 /PRNewswire/ -- In a shifting global landscape, clarity matters. From 27 to 29 May, Vinexpo Asia 2025 gathered 8,998 trade participants at Marina Bay Sands, reinforcing its position as both a business catalyst and a strategic forum for market orientation and collective foresight. The opening ceremony, attended by Singapore's Minister of State (MOS) for Foreign Affairs and Trade & Industry, Gan Siow Huang, and 15 ambassadors, set the tone for an event anchored in economic diplomacy. In her keynote address, MOS Gan underlined Singapore's commitment to "working with like-minded partners around the world" to "uphold free and open trade" — a message that echoes across the exhibition hall. "The wine and spirits industry is at a global turning point," says Rodolphe Lameyse, CEO of Vinexposium. "With so many uncertainties reshaping global trade, Southeast Asia emerges as a new consumption continent. This is no time for solo moves — it's about playing as a team. And Vinexpo Asia offers precisely the field for that. Our responsibility is clear: bring structure, perspective, and clarity." SOUTHEAST ASIA: FROM EMERGING TO ESSENTIAL Vinexpo Asia 2025 underscored Southeast Asia's strengthening position as a dynamic and collective force in the global wine and spirits trade. From Thailand to Vietnam, Malaysia to Indonesia and the Philippines, the ASEAN bloc demonstrated a shared momentum driven by demographic growth and economic ambition. The presence of ambassadors and institutional representatives throughout the show further reinforced the regional cohesion and international relevance of the event. As MOS Gan noted in her address, the region is "home to over 600 million people and a young, rising middle class, and is expected to become the world's fourth-largest economy by 2030." She also highlighted that "alcohol beverage revenue in Southeast Asia is projected to grow by about 10% from 2023 to 2027". This confirms the region's shift from emerging to essential. As a regional trade hub, Singapore provides an ideal environment to gather Southeast Asian buying power in one place. THE BUSINESS PULSE OF THE REGION With 4,253 meetings scheduled, Vinexpo Asia confirmed its role as an engine for qualified business encounters. The 2025 edition stood out for the intensity and quality of exchanges facilitated by Vinexposium's business matching platform — a tool widely praised by exhibitors for its efficiency. Buyers came from over 60 countries, with a particularly strong showing from Southeast Asia. Local professionals from Singapore were joined by decision-makers from Malaysia, Thailand, Vietnam, Indonesia and the Philippines — underscoring the region's centrality to the show. "It's always very exciting to be at Vinexpo Asia, it's an annual activity for us. We meet our partners and explore new brands to introduce in Malaysia. Being here speeds up the process," says Wilson Khor, Marketing Brand Manager at Luen Heng F&B. Among the exhibitors, national and regional pavilions from France, Italy, China, the USA and Australia drew sustained attention. For many, the show delivered concrete commercial outcomes. "Vinexpo Asia 2025 has proven to be an exceptional platform for Italian wines. The quality of the crowd—comprised of highly knowledgeable buyers, distributors, and industry leaders, was truly impressive,", affirms Giorgio Calveri, Director of the Italian Trade Agency (ITA) in Singapore. "We met the Asian importers we work with and confirmed some orders. We also met potential distributors from Malaysia and Cambodia, which are countries we are not represented in," explains Vivien Gay, Director of International Sales at Silver Oak Winery (United States). Beyond the show floor, Singapore's vibrant gastronomic scene provided an ideal backdrop for after-hours networking, a natural extension of Vinexpo Asia's blend of business, intelligence and hospitality. GUIDING THE TRADE THROUGH COMPLEXITY That same spirit of openness and dialogue continued at Vinexpo Academy — the event's strategic compass, where over 30 conferences and masterclasses addressed the forces transforming the industry, from shifting consumption patterns to emerging distribution models and new regional players. "Vinexpo Academy is the number one reason I attend Vinexposium events," shares Nimmi Malhotra, Wine Communicator. "Vinexpo Asia is a world-class ideas forum — a space for thought leadership and intellectual growth." The second issue of Voice of the Industry, Vinexposium's editorial publication, was launched onsite with a sharp focus on Asia. Distributed throughout the show, it provided expert analysis, data-driven foresight, and field-based observations. Meanwhile, four episodes of the Voice by Vinexposium podcast were recorded live in Singapore, covering key themes such as the reinvention of Southeast Asia's distribution models, the rise of premium spirits, and how identity and collectability are redefining brand strategies. Episodes will be released post-event. "In a world of shifting alliances and uncertain flows, Vinexposium stands as a trusted third party for the global drinks trade — a beacon where producers, buyers, and policymakers can connect, exchange, and build long-term strategies," concludes Rodolphe Lameyse, CEO of Vinexposium. "And following our DNA, we do business with taste, heart and soul," he adds. This strategic momentum continues in 2026, as Vinexpo Asia returns to Hong Kong from 26 to 28 May, at the Hong Kong Convention and Exhibition Center (HKCEC). Alternating between Singapore and Hong Kong, the event ensures a consistent presence across two distinct ecosystems, ASEAN and Greater China — each with its own dynamics and opportunities. For more information, visit Vinexpo Asia website Click here to access photos of Vinexpo Asia 2025 UPCOMING EVENTS Vinexpo India – 3-4 October 2025, Mumbai Vinexpo Explorer – 6-9 October 2025, Mendoza WBWE – 24-25 November 2025, Amsterdam Wine Paris – 9-11 February 2026, Paris Vinexpo Americas – 29-30 April 2026, Miami Vinexpo Asia – 26-28 May 2026, Hong Kong About Vinexpo Asia Vinexpo Asia is a premier event for wine and spirits professionals, offering exclusive access to key stakeholders in the Asia-Pacific region. Taking place alternately in Singapore and Hong Kong, two major business hubs, it serves as a strategic platform for networking, discovering industry innovations, and fostering business opportunities in one of the most dynamic markets worldwide. About Vinexposium Vinexposium is the year-round ally to the global wine and spirits trade. Through international business events and editorial content, it brings together every segment of the industry to foster growth and visibility. By combining market insight and connection opportunities, including Voice of the Industry, Vinexposium helps professionals, around the world, navigate change, unlock opportunities, and stay aligned with emerging trends in sustainability, innovation, and consumer expectations. FOR ASIAN MEDIA CONTACTS Jenny TAN FoodCult Pte Ltd words@ +65 9836 7653 Rachel RAEBURN FoodCult Pte Ltd vinexpoasia@ +65 9742 5770 ALL OTHER MEDIA REGIONS CONTACTS Camille CORDASCO Vinexposium Cloé SEBAN Vinexposium View original content to download multimedia: SOURCE Vinexposium Sign in to access your portfolio
